173 related articles for article (PubMed ID: 38791933)
1. Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery.
Mehl J; Akhoundova D; Bacher U; Jeker B; Rhyner Agocs G; Ruefer A; Soltermann S; Soekler M; Winkler A; Daskalakis M; Pabst T
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791933
[TBL] [Abstract][Full Text] [Related]
2. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
Chhabra S; Callander N; Watts NL; Costa LJ; Thapa B; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Anderson LD; Bal S; Dhakal B; Nathwani N; Shah N; Medvedova E; Bumma N; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Schmidt T; Orlowski RZ; Shain KH; Cowan AJ; Dholaria B; Cornell RF; Jerkins JH; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG; Voorhees PM
Transplant Cell Ther; 2023 Mar; 29(3):174.e1-174.e10. PubMed ID: 36494017
[TBL] [Abstract][Full Text] [Related]
3. Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience.
Thurlapati A; Roubal K; Davis JA; Shah SZ; Smith D; McGann M; Gaffney K; Cendagorta A; Maldonado A; Weeda E; Hashmi H
Transplant Cell Ther; 2023 May; 29(5):340.e1-340.e4. PubMed ID: 36804934
[TBL] [Abstract][Full Text] [Related]
4. Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation.
Eleutherakis Papaiakovou E; Terpos E; Kanellias N; Migkou M; Gavriatopoulou M; Ntanasis-Stathopoulos I; Fotiou D; Malandrakis P; Theodorakakou F; Spiliopoulou V; Kostopoulos IV; Tsitsiloni O; Tsirigotis P; Dimopoulos MA; Kastritis E
Leuk Lymphoma; 2023 Dec; 64(13):2140-2147. PubMed ID: 37655597
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Voorhees PM; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Murphy S; Lutska Y; Pei H; Ukropec J; Vermeulen J; de Boer C; Hoehn D; Lin TS; Richardson PG
Blood; 2020 Aug; 136(8):936-945. PubMed ID: 32325490
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients.
Zappaterra A; Civettini I; Cafro AM; Pezzetti L; Pierini S; Anghilieri M; Bellio L; Bertazzoni P; Grillo G; Minga P; Pioltelli ML; Ravano E; Sassone M; Viganò CV; Volpato EB; Gambacorti-Passerini C; Rossini S; Cairoli R; Crocchiolo R
Blood Transfus; 2024 Jan; ():. PubMed ID: 38315530
[TBL] [Abstract][Full Text] [Related]
7. Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.
Rybinski B; Rapoport AP; Badros AZ; Hardy N; Kocoglu M
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e716-e729. PubMed ID: 35504807
[TBL] [Abstract][Full Text] [Related]
8. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.
Yang C; Dehghani M; Hopman W; Bhella S
J Clin Apher; 2022 Aug; 37(4):348-353. PubMed ID: 35218068
[TBL] [Abstract][Full Text] [Related]
9. Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
Kauer J; Freundt EP; Schmitt A; Weinhold N; Mai EK; Müller-Tidow C; Goldschmidt H; Raab MS; Kriegsmann K; Sauer S
BMC Cancer; 2023 Nov; 23(1):1132. PubMed ID: 37990162
[TBL] [Abstract][Full Text] [Related]
10. Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma.
Sauer S; Kriegsmann K; Nientiedt C; Schmitt A; Müller-Tidow C; Raab MS; Kauer J
Transfus Med Hemother; 2023 Oct; 50(5):371-381. PubMed ID: 37936633
[TBL] [Abstract][Full Text] [Related]
11. The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.
Moreb JS; Lantos L; Chen F; Elliott K; Dugan J; Skarbnik AP; Kropf PL; Ward K
Transfus Apher Sci; 2023 Dec; 62(6):103787. PubMed ID: 37704508
[TBL] [Abstract][Full Text] [Related]
12. A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation.
Bittrich M; Kriegsmann K; Tietze-Stolley C; Movassaghi K; Grube M; Vucinic V; Wehler D; Burchert A; Schmidt-Hieber M; Rank A; Dürk HA; Metzner B; Kimmich C; Hentrich M; Kunz C; Hartmann F; Khandanpour C; de Wit M; Holtick U; Kiehl M; Stoltefuß A; Kiani A; Naumann R; Scholz CW; Tischler HJ; Görner M; Brand F; Ehmer M; Kröger N
Transfus Med Hemother; 2023 Dec; 50(6):475-490. PubMed ID: 38089497
[TBL] [Abstract][Full Text] [Related]
13. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Moreau P; Hulin C; Perrot A; Arnulf B; Belhadj K; Benboubker L; Béné MC; Zweegman S; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Mohty M; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Macro M; Orsini-Piocelle F; Roussel M; Stoppa AM; van de Donk NWCJ; Wuillème S; Broijl A; Touzeau C; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Offner F; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Krevvata M; Zhang K; de Boer C; Vara S; Kampfenkel T; Vanquickelberghe V; Vermeulen J; Avet-Loiseau H; Sonneveld P
Lancet Oncol; 2021 Oct; 22(10):1378-1390. PubMed ID: 34529931
[TBL] [Abstract][Full Text] [Related]
14. Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.
Yuan S; Palmer JM; Tsai NC; Dagis A; Nademanee A; Wang S
Hematol Oncol; 2017 Sep; 35(3):281-287. PubMed ID: 26928577
[TBL] [Abstract][Full Text] [Related]
15. Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma.
Damron EP; Qazilbash MH; Fang PQ; Wu SY; Dabaja BS; Rondon G; Hosing C; Champlin RE; Bashir Q; Shpall EJ; Knafl MK; Lee HC; Manasanch EE; Patel K; Thomas SK; Orlowski RZ; Weber DM; Pinnix CC; Gunther JR
Transplant Cell Ther; 2023 Jan; 29(1):37.e1-37.e7. PubMed ID: 37753818
[TBL] [Abstract][Full Text] [Related]
16. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
Laszlo D; Marcacci GP; Martino M; Radice D; Rabascio C; Lucchetti B; Magarò A; Caime A; Menna S; Lionetti MT; Bertolini F
Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108
[TBL] [Abstract][Full Text] [Related]
17. Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.
Elayan MM; Horowitz JG; Magraner JM; Shaughnessy PJ; Bachier C
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1921-5. PubMed ID: 26033279
[TBL] [Abstract][Full Text] [Related]
18. A comparison of peripheral blood stem cell collection outcomes for multiple myeloma; mobilization matters in the era of IMiD induction.
Chandler T; Parrish C; Karakantza M; Carmichael J; Pawson D; Cook G; Seymour F
EJHaem; 2023 Aug; 4(3):625-630. PubMed ID: 37601867
[TBL] [Abstract][Full Text] [Related]
19. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
Stiff PJ; Micallef I; Nademanee AP; Stadtmauer EA; Maziarz RT; Bolwell BJ; Bridger G; Marulkar S; Hsu FJ; DiPersio JF
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1146-53. PubMed ID: 21126595
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]